One trader believes Rockwell shares will rise into clinical trial results expected in July.
The market overreacted to the resignation of Synta's R&D chief.
Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.
Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.
I expect traders will get an opportunity to profit from increased focus on Titan through March.
Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.
Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.
Anacor will be releasing phase III results for a toenail fungus drug in January.
FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.
Alexza expects US and European regulators to announce approval decisions in December.